Targeted biopsy of the prostate
- PMID: 38976055
- DOI: 10.1007/s00261-024-04452-z
Targeted biopsy of the prostate
Abstract
Diagnostic multiparametric MRI of the prostate has steadily evolved over the last three decades and can now reliably depict the dominant tumor in most men with prostate cancer. In response, several methods of targeted biopsy to direct tissue sampling of suspected tumor foci seen at multiparametric MRI have been developed and successfully tested in recent years, including software-assisted MRI-ultrasound (US) fusion biopsy and direct MRI-guided in-bore biopsy. These advances are leading to a sea change in the approach to prostate cancer diagnosis, with the traditional approach of blind systematic biopsy increasingly being replaced by MRI directed targeted biopsy. This review aims to describe the current status of targeted biopsy, with an emphasis on the relative accuracy of different techniques. The results of several critical large multicenter trials are presented, while unanswered questions that require more research are highlighted.
Keywords: Biopsy; Cancer; MRI; Prostate; Transrectal ultrasound.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: Founder and shareholder in and consultant to OmnEcoil Instruments, Inc.
References
-
- American Cancer Society. Cancer Facts and Fig. 2024. Atlanta: American Cancer Society; 2024: 4.
-
- https://progressreport.cancer.gov/after/economic_burden#field_most_recen... . Accessed May 27, 2023.
-
- Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M, and PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2019; 389: 815–822. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical